Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts
about
hVMAT2: A Target of Individualized Medication for Parkinson's Disease.The dopamine transporter role in psychiatric phenotypes.(AZI2)3'UTR Is a New SLC6A3 Downregulator Associated with an Epistatic Protection Against Substance Use Disorders.Cannabinoid type 2 receptors in dopamine neurons inhibits psychomotor behaviors, alters anxiety, depression and alcohol preference.
P2860
Increased Nigral SLC6A3 Activity in Schizophrenia Patients: Findings From the Toronto-McLean Cohorts
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@ast
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@en
type
label
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@ast
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@en
prefLabel
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@ast
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@en
P2093
P2860
P356
P1476
Increased Nigral SLC6A3 Activi ...... rom the Toronto-McLean Cohorts
@en
P2093
Clement C Zai
Deborah L Levy
Eden Martin
James L Kennedy
Jennie G Pouget
Jinlong Yu
Nian Xiong
P2860
P304
P356
10.1093/SCHBUL/SBV191
P407
P50
P577
2015-12-26T00:00:00Z